Strides Arcolab is trading higher by 4% to Rs 643, extending its previous day’s over 1% gain, after foreign institutional investors (FIIs) have bought nearly 1 percentage points of stake in pharmaceutical company through open market transactions.
Goldman Sachs and Morgan Stanley has collectively purchased 626,212 equity shares representing 1.05% stake in Strides Arcolab in past two trading sessions, the BSE bulk deal data shows.
On June 11, Goldman Sachs Investments Mauritius has bought 300,000 shares at Rs 626.28 per share, while on June 10, Morgan Stanley Asia (Singapore) PTE purchased 326,212 shares at Rs 623.62 per share, according to information available on the stock exchange.
The stock opened at Rs 626 and hit a 52-week high of Rs 648 on the BSE. A combined 440,314 shares changed hands on the counter till 1025 hours on the BSE and NSE.
Meanwhile, so far in current month, the stock has rallied 26% against 5.5% rise in benchmark S&P BSE Sensex and 4.2% rise in S&P BSE Healthcare index.
Goldman Sachs and Morgan Stanley has collectively purchased 626,212 equity shares representing 1.05% stake in Strides Arcolab in past two trading sessions, the BSE bulk deal data shows.
On June 11, Goldman Sachs Investments Mauritius has bought 300,000 shares at Rs 626.28 per share, while on June 10, Morgan Stanley Asia (Singapore) PTE purchased 326,212 shares at Rs 623.62 per share, according to information available on the stock exchange.
The stock opened at Rs 626 and hit a 52-week high of Rs 648 on the BSE. A combined 440,314 shares changed hands on the counter till 1025 hours on the BSE and NSE.
Meanwhile, so far in current month, the stock has rallied 26% against 5.5% rise in benchmark S&P BSE Sensex and 4.2% rise in S&P BSE Healthcare index.